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CT-image based conformal high-dose-
rate brachytherapy boost in the conserva-
tive treatment of stage I – II breast cancer 
– introducing the procedure
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Summary
aim: Breast-conserving surgery (BcS) followed by radiotherapy (Rt) has become the standard treat-
ment for the majority of patients with early breast cancer. With regard to boost technique some 
disagreements are found between groups that are emphasizing the value of electron boost treatment 
and groups pointing out the value of interstitial brachytherapy (Bt) boost treatment. We present the 
preliminary results in treating selected patients with early-stage breast cancer using high-dose-rate 
brachytherapy (hdR-Bt) as a boost after breast conservation therapy (Bct). 
materialS/methodS: Between January 2006 and August 2007, a total of 58 female patients with 
first and second stage breast cancer underwent BCT. This therapeutic procedure involves BCS, whole 
breast radiation therapy (WBRt) and additional irradiation to the tumour bed (boost) using interstitial 
HDR-BT via flexible implant tubes. A 10 Gy boost dose was received by all patients. The treatment 
planning was based on CT-guided 3D (three-dimensional) reconstruction of the surgical clips, implant 
tubes and critical structures localization (skin and ribs). The accuracy of tumour bed localization, the 
conformity of planning target volume and treated volume were analyzed.
reSultS: The evaluations of implant parameters involved the use of: dose volume histogram (DVH), 
the volume encompassed by the 100% reference isodose surface (V100%), the high dose volume 
calculation (V150%, V200%, V300%), the dose non-uniformity ratio (DNR), and the conformity in-
dex (COIN). Our results were as follows: the mean PTV volume, the mean high dose volume (V150%; 
V200%; V300%), the DNR and COIN mean value were estimated at 57.38, 42.98, 21.38, 7.90, 0.52 and 
0.83 respectively.
ConCluSionS: CT-guided 3D HDR-BT is most appropriate for planning the boost procedure after BT 
especially in large breast volume, in cases with a deep seated tumour bed, as well as in patients with 
high risk for local recurrences. This technique reduces the possibility of geographical miss. Moreover, 
better conformity could be achieved between planning the target volume and the treated volume, 
even at the cost of worse dose homogeneity. The irregular 3D shape of the target volume and the 
normal tissue structures can be correctly localized on the basis of visual information obtained from 
cross-sectional ct imaging. Better local control rate with fewer side effects might be achieved with 
this technique based on ct imaging.  
Key wordS: breast-conserving therapy, radiotherapy, hDR brachytherapy, boost, CT-based 
treatment planning.
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BaCKground
Over the past century, breast cancer treat-
ment has experienced a lot of significant and 
historic changes. From radical Halsted mas-
tectomy to the current era of breast conserva-
tion surgery, RT has steadily integrated itself 
into the management of breast cancer [1–3]. 
Today with the availability of modern diag-
nostic imaging facilities allowing detection of 
early stages of breast cancer, along with the 
integration of sophisticated RT techniques, 
BCT is widely accepted as an alternative 
to mastectomy in the management of early 
breast cancer [4]. Even the concept of tumour 
bed RT alone (partial breast irradiation, PBI) 
as an alternative to whole breast RT in BCT, 
was evaluated in patients with low risk of re-
lapse [5, 6]. The standard procedure of BCT 
involves conservation surgery (tumourectomy, 
lumpectomy, quadrantectomy and axillary 
sampling), radiation of residual breast tissue 
(with or without regional nodal irradiation) 
and – if needed – additional systemic therapy. 
The main purpose of radiation in BCT is to 
prevent any local recurrence without effect-
ing cosmetic outcome [7–14]. Conventionally 
RT in BCT includes WBRT that is usually de-
livered by tangential beams. A supplementary 
tumour bed boost dose of 10–20 Gy (either 
through electrons, photons or an interstitial 
implant) is added to decrease the rate of lo-
cal recurrence. A considerable number of sci-
entific discussions have been focused on the 
optimal technique of delivering the radiation 
boost [15]. Moreover, the role of boost dose in 
a patient with negative margins of resection 
was questioned [16]. However, the use of BT 
as additional irradiation to the tumour site 
with early stage breast cancer has increased 
significantly over the past several years [7, 8, 
17–19]. With regard to boost technique, there 
are certain disagreements between groups 
emphasizing the value of electron boost treat-
ment and groups pointing out the value of in-
terstitial boost therapy [11, 15, 20]. However, 
there are patients for whom electrons may be 
less appropriate. They include patients with 
large breasts and deep tumour location where 
electron boosting may result in excessive skin 
dose or even increased dose to the underly-
ing lung. The big advantage of BT over exter-
nal beam radiotherapy (EBRT) is the much 
Fig. 1. TK image showing surgical clips necessary 
for tumour bed localization 
smaller and more conformal irradiation to 
the target volume due to the rapid dose fall-
off [11, 15, 21, 22]. Nowadays the indication 
of the boost after BCT and selection of the 
proper technique in order to deliver an extra 
dose should depend on clinical and morpho-
logical criteria as well as patients’ agreement. 
At present there are several techniques used 
in maintaining better coverage of the target 
volume. However, the irregular 3D shape 
of the excision cavity and the normal tissue 
structures can only be accurately localized 
by visual information acquired from cross-
sectional imaging. The use of surgical clips 
and CT at the same time seems to be the best 
method to determine the target volume, since 
both titanium clips and borders of the excision 
cavity can be visualized exactly from slice to 
slice [23–25]. A CT scan with visible clips is 
presented in Figure 1.
aim
We present the preliminary findings of our 
treatment protocol that involves radiation 
boost after breast conservation therapy (BCT) 
in selected patients with early-stage breast 
cancer using high-dose-rate brachytherapy 
(HDR-BT). We also review the current status, 
indications, technical aspects and future pros-
pects of boost irradiation after BCT.
materialS
Patients and tumour characteristics 
Between January 2006 and August 2007, 58 
female patients with stage I and II breast can-
cer underwent BCT. This therapeutic proce-
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dure comprises BCS, WBRT and a boost of 
additional irradiation to the tumour bed using 
interstitial HDR-BT via flexible implant tubes. 
Most of the patients were premenopausal, 
with high risk for local recurrence as a conse-
quence of a close, positive margin and exten-
sive intraductal component (EIC) presence. 
None of the patients were showing symptoms 
of systemic metastasis based on clinical ex-
amination, liver function test, chest X-ray and 
ultrasound abdomen at the time of BCT. Pa-
tients with indications of bone pain underwent 
a skeletal survey. All patients were subjected 
to a mammogram test in order to rule out mul-
ticentric ipsilateral disease as well as contral-
ateral breast cancer. Post-operative specimen 
analysis revealed invasive ductal carcinoma 
in 32 of the patients, invasive lobular carci-
noma in 13 and other types of cancer in 10 
cases, where a positive margin was noted in 8 
of them. EIC defined as more than 25% of tu-
mour composition and intraductal component 
was present in 15 patients with negative re-
sected margin. In Table I summarized clini-
cal data are presented.
methodS
treatment procedure 
Surgery
All of the patients underwent BCS, of which 
there was: tumourectomy, lumpectomy, quad-
rantectomy with 15, 16 and 27 patients, re-
spectively. During surgery, the margins of the 
excision cavity were marked with 2 to 6 titani-
um clips. Axillary dissection was performed 
in all patients with cancer stage I and II. Five 
of the patients underwent re-excision in an at-
tempt to achieve a clear margin. A total of 18 
of the cases reported the final margin status at 
less than 2 mm. The data of six patients were 
ultimately documented with a focally positive 
margin.
EBRT
All patients received EBRT to the entire 
breast using wedge tangential 6 MV photon 
fields. Three schedules of external beam 
radiotherapy (EBRT) were applied before 
patient admission to the Department of 
Brachytherapy (Table 2). For patients with 
negative axillary lymph nodes (pN0) or with 
metastasis < 2mm (pN1a), regional nodal ir-
Clinical data Number of patients
Age (years):
< 40 4
41–50 28
51–60 18
> 60 8
All: 58
Menopausal status:
Premenopausal 32
Postmenopausal 26
Pathological stage:
Tumour (pT):
pT1a 5
pT1b 15
pT1c 20
pT2 15
pTx 3
Node involvement (pN):
pNo 45
pN+ 13
Histology:
DCIS 3
IDC 32
ILC 13
others 10
Grading:
G1 10
G2 28
G3 20
EIC present 15
Receptor status:
Positive 48
Negative 10
Surgical margin:
Clear 29
Close < 2mm 18
Positive 8
Not available 3
DCIS: ductal carcinoma in situ; IDC: infiltrative ductal 
carcinoma; ILC: infiltrative lobular carcinoma; EIC: 
extensive intraductal component
Table 1. Patient and tumour characteristics
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radiation (RNI) was omitted. The remaining 
patients received RNI by an anterior supra-
clavicular/axillary field on account of risk of 
subclinical involvement of regional lymph 
nodes. After receiving EBRT with one to a 
few days’ break, the brachytherapy boost 
treatment was delivered.
HDR-BT
The HDR-BT was preferred as a boost par-
ticularly for a deeply seated tumour bed in 
large volume breasts (deeper than 10 mm un-
der the epidermis) and in cases of high risk 
of local recurrence (close or positive surgi-
cal margin with EIC present). During the 
procedure after breast conservation surgery 
the patients were subjected to tumour bed 
implantation with a flexible implant, guided 
by an individually created template for each 
patient, based on the patient’s breast volume 
and tumour characteristics. An example of 
the procedure is presented in Figure 2. Two 
sets of pre- and post-implant CT scans were 
performed. The HDR-BT was delivered with 
an HDR Microselectron unit. A dose of 10 Gy 
was given in one fraction. 
Indications for interstitial HDR-BT were as 
follows: 1. Interstitial HDR-BT of the primary 
tumour site after breast conserving surgery 
and/or chemotherapy and WBRT. 2. Intersti-
tial HDR-BT of the primary tumour bed after 
neoadjuvant chemotherapy, BCS in the high 
risk group for local recurrence group and 
WBRT. 
Contraindications for interstitial boost ir-
radiation included: 1. multicentric breast can-
cer; 2. Paget’s disease alone or in association 
with a breast lump; 3. superficially located tu-
mour bed in small breasts; 4. lack of patient 
agreement and preference for EBRT boost 
method.
Systemic therapy
Adjuvant chemotherapy consisted of AC 
(adriamycin-cyclophosphamide) in 33 of the 
patients, CMF (cyclophosphamide-methotrex-
ate-5 FU) in 8, neoadjuvant chemotherapy ac-
cording to AC programme in 2 of the cases, 
respectively. A total of forty-eight patients re-
ceived adjuvant hormone therapy.
CT-based treatment boost planning – tar-
get volume delineation
Every individual case of BT target volume 
was based on combined information from the 
pathologic evaluation (factors considered in-
cluded excision specimen size, tumour loca-
tion within the resected specimen, character-
istics of surgical margins, histological type) 
mammographic and ultrasound findings, 
clinical examination (scar position, size and 
location of any palpable seroma), localization 
of surgical clips, as well as CT pre-implant 
cross-sectional imaging (both exact visibility 
of titanium clips and borders of the slice to 
slice excision cavity). The clinical target vol-
Number  
of applications
Total 58
Number  
of applicators
Median 7
Range 3–12
PTV [cm3] Median 57.38
Range 15.77–177.48
Reference Dose [Gy] 10
Optimization Manual 23
On reference 
points 29
Geometrical 5
PTV – planning treatment volume
Table 3. Description of applications
Fig. 2. Interstitial applicators inserted into breast,  
9 applicators visible
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ume (CTV) was defined by a margin of 2 cm of 
breast tissue of the primary tumour, since this 
area contains 80% of the microscopic tumour 
extensions. The planning target volume (PTV) 
was comparable to the CTV for the reason that 
extra margin added in case of organ motion 
or set-up errors is not required in interstitial 
BT. The CTV of boost irradiation was not fo-
cused on such critical structures as the ribs 
and breast skin with tissues beyond the fascia 
such as thoracic wall muscle. The minimum 
distance from the PTV to skin and underly-
ing ribs was 10 mm. This helped to define the 
dimensions of the boost volume, as well as the 
choice between electron beam boost and inter-
stitial implants. 
Technique of implantation
BT catheter placement and treatment de-
livery were conducted on an outpatient basis. 
Equipment used in implantation included: 16–
20 cm long implantation needles (guide nee-
dles), templates in different sizes (channels in 
square or triangular arrangement and with 
distances of the channels in the range 12–20 
mm) depending on the thickness of the breast 
(the thicker the breast, the larger the template 
and spacing used), ruler for measurement of 
the skin distance, plastic tubes, and buttons to 
immobilize inserted catheters. The treatment 
procedure was performed under general an-
aesthesia. The patient was placed in a supine 
position with ipsilateral arm in 90 abduction. 
Once the PTV was defined, the implant geom-
etry was designed according to the rules of the 
Paris System:
1. Needles were implanted parallel and 
equally distant from each other. The direction 
of implant depended on tumour cavity local-
ization and it was selected in such a way as 
to enable adequate PTV covering and at the 
same time to avoid overlapping of source po-
sitions in critical structures (minimum 1 cm 
distance from critical structures was taken 
into account). In most cases, the needles were 
inserted in a lateral-medial direction. When 
the PTV localization was in the upper outer 
quadrant, 45-degree angle needle implanta-
tion was frequently applied. 
2. Needles in two planes were usually re-
quired to cover the PTV procedure. A single 
plane was sufficient in the case of flat breast 
target thickness of less than 12 mm. Three 
planes were required in a large breast tar-
get thickness of more than 30 mm. In the 
case of implantation on two or more planes, 
needles were disposed either in a triangular 
or a square pattern. Moreover, the triangular 
configuration was better adopted to follow the 
breast skin contour whenever the PTV was 
placed close to the skin.
3. The first needle (the so-called guidance 
or reference needle) was placed within the 
deepest place of the tumour bed and in the 
centre of the lowest level of the implant. The 
rest of the needles were inserted in order to 
adequately cover the PTV. To ensure that the 
following needles would be implanted parallel 
and equally distant from each other, an appro-
priate size template was placed over the guid-
ance needle. Number and spacing between 
template size needles was chosen to cover 
sufficiently the width and the thickness of the 
PTV. Guide needles were replaced by plastic 
tubes immobilized by buttons at both sides of 
the breast.
4. Positioning verification of the plastic 
tubes with the help of the CT unit. A CT post-
implant scan was performed every 3 mm dur-
ing the procedure and transferred directly to 
the PLATO System. The CT-based planning 
allowed surgical clips to be localized and a 
sufficient distance to be maintained between 
implant tubes and overlying skin and under-
lying ribs. In our study after the pre-implant 
simulation 3 to 14 (mean 7) guide needles were 
inserted into the previously targeted area in 
a triangular or square setting with template 
guidance. Single, double and triple plan im-
plant was performed in 6, 40 and 20 cases, re-
spectively. We used three methods of dose op-
timization: manual – 23 cases; on dose points 
– 29; and geometrical – 5 of the patients. 
CT-based treatment planning procedure
3D treatment planning based on a CT cross-
sectional image was performed in all cases. 
The main aspect of our practice was to achieve 
such dose distribution that all surgical clips 
would receive at least 85% of the prescribed 
dose. Our planning concepts were based on 
the 3D reconstruction of the catheters, tu-
mour bed clips maintaining proper distanc-
es (at least 10 mm) from critical structures 
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(skin, ribs). Some examples of 3D treatment 
plans are presented in Figures 3–7. The active 
source positions, dwell times and reference 
dose points were defined individually in each 
catheter as well as dose optimization. To avoid 
skin and rib injury, the most peripheral active 
source positions were kept at a minimum of 10 
mm distance from the skin and rib surface. 
Follow-up and treatment assessment
All patients completed the boost treatment 
and were placed on follow-up (operating for 
over a year). The first control visit was one 
month after completion of the BCT procedure. 
Subsequent visits were scheduled once every 
3 months until the end of the first year of fol-
low-up. During the visits, certain important 
factors were evaluated such as: local control 
Fig. 3. 3D imaging of chest and interstitial ap-
plicators. Yellow colour – chest contour 
Fig. 4. TK image with applicators (blue and green 
colour) before planning – first stage 
Fig. 5. TK image with applicators (blue and green 
colour) – after optimization (blue points), red 
colour – reference isodose 
Fig. 6. The same image as Fig. 5, dwell-steps 
visible
Fig. 7. 3D image of treated target (tumour bed 
with margin) – red colour 
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(LC), disease-free survival (DFS), cosmetic 
result and quality of life according to the gen-
eral questionnaire EORTC Q-30 and the mod-
ule EORTC QLQ-BR-23 specific for breast 
cancer. Tumour control was assessed by clini-
cal examination, serum biochemistry, radio-
logical investigations (annual X-ray, abdomen 
USG, mammogram – the first time six months 
after completion of BCT). Cosmetic result 
was scored objectively by the treating physi-
cian and subjectively by the patient. Clinical 
examination and taking a photograph of the 
patient’s breasts were the basis for the objec-
tive cosmetic evaluation. The overall cosmetic 
outcome was scored according to the scale: 
excellent (perfect symmetry, no visible dis-
tortion), good (slight distortion of nipple/skin 
with visible telangiectasia and mild hyperpig-
mentation), acceptable (moderate distortion, 
breast asymmetry, moderate hyperpigmenta-
tion, prominent skin retraction or telangiecta-
sia), poor (marked distortion of nipple, breast 
asymmetry, oedema, fibrosis, severe hyper-
pigmentation). 
reSultS
Preliminary results are promising. None of the 
patients have experienced local relapse to date 
and local control in this study was achieved 
in 100%. Only one patient developed a distant 
metastasis during follow-up and subsequently 
received appropriate palliative RT along with 
second line chemotherapy (at the time of this 
report the patient is still alive). Acute toxicity 
including transient erythema, breast swelling 
and skin reaction at the needle puncture sites 
was healed subsequently with conservative 
treatment. None of the patient experienced lo-
cal infection. However, after removing cathe-
ters, two patients acquired breast haematoma. 
So, in order to avoid late toxicity some cases 
required longer follow-up.
In the analysis of conformity of the PTV and 
treated volume we involved the use of: cumu-
lative dose-volume histograms (DVH), high 
dose volumes calculation (V150%, V200%, 
V300%) as recommended by ICRU Report 58 
[26], the mean volume encompassed by the 
100% reference isodose surface (V100%), the 
dose uniformity ratio (DNR), defined as the 
ratio of the 150%  high dose volume (V150%) 
to the 100% reference dose volume (V100%), 
conformity index (COIN), optimization of 
dose distribution (three methods of optimiza-
tion: manual, on reference points, geometri-
cal). Results of evaluated parameters are pre-
sented in Tables 3–4. 
diSCuSSion
BCT has become widely accepted in the last 
decades as the treatment of early invasive 
breast cancer [1–3]. The rationale of boost-
ing the primary tumour bed up to 60–70 Gy is 
based on evidence that the majority (50–80%) 
of local recurrences appear in or close to the 
same quadrant where the primary tumour 
was located [8, 9]. A clear dose-local control 
relationship for doses > 45 Gy was found by 
several authors [3, 8, 13, 19, 22, 24, 27, 28]. 
Institutional experience and a large random-
ized trial suggested improved local control 
which resulted from boosting the area of the 
tumour bed with an adequate safety margin 
(Table 5). However, the precise indications 
for boost irradiation are not well established. 
Factors including insufficient surgical mar-
gins, young age, unfavourable histopathologic 
criteria such as EIDC, high grade of malig-
nancy, tumour necrosis and endolymphatic 
extension were described as the predisposing 
circumstances to develop local recurrences 
[14, 15, 16]. Re-excision is considered in the 
case of negative margins measuring less than 
2 mm and focally positive margins. Whenever 
Treatment strategy Number of patients
Surgery:
   Tumourectomy 15
   Lumpectomy 16
   Quadrantectomy 27
WBRT (total dose in Gy,  
dose per fraction, number of 
fractions)
   42.5 / 2.5 / 17 30
   45 / 2.25 / 20 20
   50 / 2 / 25 8
   Regional nodal irradiation 10
Adjuvant Chemotherapy 45
Adjuvant Hormone therapy 48
Table 2. Treatment strategy
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additional surgery is not considered appropri-
ate, a boost dose even up to 20 Gy should be 
delivered either with electrons or interstitial 
BT. The optimal boost technique (electron vs. 
brachytherapy) and its impact on local tumour 
control and cosmetic result [15, 28, 31, 32] is 
creating some controversy. Based on the re-
sults of numerous retrospective and recently 
published forthcoming trials, the European 
Brachytherapy Society (GEC-ESTRO) and the 
American Brachytherapy Society (ABS) have 
issued their guidelines regarding these sub-
jects [33, 34], which will help clinicians in their 
medical decisions. In the generally accepted 
treatment plan all patients should be routinely 
boosted where the 5-year local recurrence rate 
after BCS and whole breast RT is assumed to 
be > 5%. This high risk subset of patients in-
volves all women aged less than 50 years, with 
a positive or close resection margin, and with 
EIC. Moreover, demarcation of the excision 
cavity by intraoperative clips should be rou-
tinely used as a minimum requirement for tar-
get volume definition. The ABS also published 
their guidelines specifically for selective use 
of BT as a boosting technique where deliver-
ing the boost irradiation with electrons can 
be problematic (large breasts, deep tumour 
location, worse prognostic factors including 
close, positive, or unknown margins, EIC, and 
young patient). Interstitial BT offers a confor-
mal dose delivery method with the ability to 
reduce the dose of unwanted irradiation to the 
skin and ribs. Satisfactory results of local con-
trol and positive cosmetic outcome were doc-
umented in performing this technique. The 
advantages of HDR brachytherapy include: 
outpatient treatment, control of patient posi-
tioning in order to ensure accuracy of treat-
ment delivery, ability to optimize dose distri-
bution, improvement in staff protection during 
radiation, much smaller and more conformal 
irradiated volume to the target volume due to 
the rapid dose fall off [15, 33–36]. It is known 
from clinical practice that deeply seated target 
volumes can be covered more accurately by 
interstitial implants than by electron beams. 
The latter method is not only associated with 
larger treatment volumes, resulting in higher 
rate of breast fibrosis, but also results in an 
Mean SD Range
D90 8.64 1.68 0.93–10.74
D100 4.30 1.68 0.50–8.33
V100 82.04 1.68 41.96–95.24
V150 42.98 1.68 10.04–60.90
V200 21.38 8.14 10.53–37.79
V300 7.90 3.03 3.74–17.27
DNR 0.52 0.11 0.14–0.68
C1 0.82 0.09 0.43–0.95
C2 0.82 0.07 0.63–1.00
COIN 0.83 0.10 0.33–0.87
D90 – the dose value which covers 90% of PTV volume [Gy] 
D100 – the dose value which covers 100% of PTV volume [Gy] 
V100 – the mean volume encompassed by the 100% reference isodose surface (V100%) 
V150 – the mean volume encompassed by the 150% reference isodose surface (V100%) 
V200 – the mean volume encompassed by the 200% reference isodose surface (V100%) 
V300 – the mean volume encompassed by the 300% reference isodose surface (V100%) 
DNR – the dose uniformity ratio defined as the ratio of the 150% high dose volume (V150%) to the 100% reference  
           dose volume (V100%), 
C1 – the fraction of PTV that is enclosed by the reference dose 
C2 – the fraction of reference dose volume that is covered by PTV 
COIN – conformity index
Table 4. Physical factors appraised in treatment plan
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increased rate of telangiectasia due to a high-
er skin dose. Applying the useful boost range 
concept, van Limbergen et al. calculated that 
the critical depth for the target volume where 
the interstitial implant has a definitely bet-
ter ballistic selectivity compared to electron 
boost is 28 mm [15, 34]. It is most advisable to 
perform the electron boost in cases of superfi-
cial and peripheral localizations of the tumour 
bed. Advantages and disadvantages of differ-
ent boost methods are summarized in Table 
6. Adequate definition of the target volume is 
the crucial point in using any boost technique. 
The boost PTV is usually defined with a 2 cm 
safety margin of the tumour bed. In the past, 
only palpation, mammograms, surgical re-
ports and scars were available landmarks to 
localize the excision cavity. Nowadays, there 
are several methods to maintain better cover-
age of the target volume. The authors of sci-
entific publications have used ultrasound (US) 
examination to localize the tumour bed. De-
Biose et al. emphasized that US was indeed an 
appropriate method for boost target definition, 
but only in the first 6–8 weeks after surgery 
[36]. Rabinovitch et al. prospectively com-
pared the precision of different methods in a 
TV definition [37]. His study revealed that the 
ultrasound examination significantly under-
estimated all three dimensions of the excision 
cavity. Furthermore, in his general conclusion 
he indicated the radiographic evaluation of 
surgical clips to be superior to US in defining 
the lumpectomy cavity. Some of the authors in 
their research delivered the HDR-BT boost 
using Iridium-192 implants at the time of sur-
gery, but before WBRT [38]. The advantage of 
this modality is the possibility of placing the 
catheters more accurately into the tumour 
bed. However, the limitation of this procedure 
is the lack of detailed histological information 
at the time of implantation. An intraoperative 
implantation demands good collaboration and 
time management between the surgeons and 
radiation oncologists. The majority of authors 
have suggested the best orientation given by 
titanium clip markers that are implanted in-
traoperatively [15, 24, 37]. Placing 6 clips into 
the walls of the excision cavity according to 
latero–medial, antero–posterior, inferior and 
superior dimensions seems to be the ideal 
approach. However, the titanium clips do not 
alter the dose distribution during RT or the 
quality of diagnostic MR images after the 
procedure. The irregular 3 dimensional (3D) 
shape of the target volume and the normal tis-
sue structures can only be correctly localized 
on the basis of visual information obtained 
from cross-sectional CT imaging. In addi-
tion to this, better local control rate with few-
er side effects might be achieved with these 
techniques based on CT imaging [24, 34, 35, 
Trial Number  
of Patients
Median  
FUP years
Boost dose 
(Gy), technique
Crude LR % – 
boost vs  
no boost
5-years 
actual LR % 
– boost vs no 
boost
5-years RFS 
% – boost vs  
no boost
Uzsoki  
Hospital [29]
111 3.8 10-20 (BT) 5.4 vs 10.7 NR NR
Nice  
Hospital[30]
664 6 10 (EBRT) 4.3 vs 6.8 NR NR
Lyon  
Hospital [8]
1024 3.3 10 (EBRT) 1.9 vs 4.0 3.6 vs 4.5 86.0 vs 82.2
EORTC [28] 5318 5.1 15-16 (EBRT/BT) 4.1 vs 6.8 4.3 vs 6.8 NR
Budapest  
Hospital [17]
207 4.8 12-16 (EBRT/BT) 6.7 vs 14.6 8.0 vs 15.7 79.5 vs 67.3
All 7324 3.9 vs 6.7
FUP: follow-up period; LR: local recurrence; RFS: relapse-free survival; EBRT: external beam radiotherapy (electrons); 
BT: brachytherapy; NR: not reported; EORTC: European Organization for Research and Treatment of Cancer
Table 5. Results of prospective breast boost trials
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39]. The combined use of surgical clips and 
CT or MRI appears to be the best method to 
determine the target volume, since both tita-
nium clips and borders of the excision cavity 
can be visualized exactly from slice to slice. 
Recently Vicini et al. and Polgar et al. imple-
mented 3D virtual brachytherapy based on 
two sets (pre- and post-implant) of CT scans. 
In their research, the 3D BT showed excellent 
agreement in target volume coverage between 
the pre-planned virtual implant geometry and 
the actual positioning of the final afterloading 
needles [40, 41].
Three dimensional (3D) treatment plan-
ning has made promising progress in the last 
decade of radiotherapy. Currently, conformal 
3D EBRT is a permanent part of routine clini-
cal work in most radiotherapy departments. 
Moreover, 3D brachytherapy treatment plan-
ning has recently become the centre of inter-
est.
The advantages of conformal brachythera-
py boost treatment planning in the manage-
ment of breast cancer are as follows: 1. as a 
useful tool helping to avoid geographical miss, 
2. the irregular 3D shape of the target volume 
and the normal tissue structures can only be 
localized correctly on the basis of visual infor-
mation obtained from cross-sectional CT-im-
aging (better local control rate with fewer side 
effects might be achieved with these technique 
based on CT imaging), 3. the primary role of 
the treatment planning and dose optimization 
for a given implantation is to achieve as good 
coverage of the target volume as possible (ad-
equate homogeneity is relatively important), 
4. verification of the positioning of the plastic 
tubes with the CT unit [42–44]. With CT-based 
planning, the distances between implant tubes 
and overlying skin and underlying ribs are di-
rectly visible and measurable. The skin dose 
should not exceed 60% of the prescribed dose 
(executed only in the case of a superficial plane 
implanted at least 10 mm from the skin).
Overall, a boost after whole breast irradia-
tion was reported to improve local tumour con-
trol in breast conservation therapy. Its efficacy 
is quite likely to correlate with tumour charac-
teristics, type of surgical procedure, status of 
resection margin, as well as technical details 
of irradiation. Preliminary results along with 
recently developed boost techniques (IORT, 
Treatment  
option
Personal 
time
Volume Total dose (Gy)/ 
Fraction/ Time
Side  
effects
Comments
BT:  
LDR  
PDR  
 
HDR 
 
+++ 
+++ 
 
++
 
+ 
+
 
25 / 1 / 2d 
25 / 50 / 2d 
 
10 /1 / min
 
+ 
+ 
 
+
 
Application time: days 
Application time: days, 
biologically comparable to LDR; 
Application time minutes, 
assumed high biological risk,  
geographical mistake risk
Intraoperative  
catheters  
placement
See LDR and HDR, 
PDR
Histological criteria for boost indica-
tions at time of surgery in part not 
available
EBRT: 
Electrons 
 
 
Photons 
 
Intraoperative 
electrons 
 
+ 
 
 
+ 
 
+++
 
++/ 
+++ 
 
++/ 
+++ 
++/ 
+++ 
 
10–20 / 5-10 / 5–10d 
 
 
10–20 / 5-10 / 5–10 d 
 
10–20 / 1 / min
 
++ 
 
 
++ 
++
 
High rates of side effects in deeply 
seated tumour bed – increased risk of 
induration, shrinkage, telangiectasia; 
High integral dose, duration  
treatment prolonged; 
Histological criteria for boost indica-
tions at time of surgery in part not 
available
LDR: low dose rate; PDR: pulsed dose rate; HDR: high dose rate
Table 6. Advantages and disadvantages of different boost methods [9]
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CT-image based 3D conformal BT and 3D vir-
tual BT) are quite promising. However, more 
experience and longer follow-up are required 
in order to define whether these methods 
might improve local tumour control for breast 
cancer patients treated with BCT.  
The majority of local recurrences appear in 
close proximity to the tumour bed; therefore 
the necessity of WBRT was questioned and 
several centres evaluated the feasibility and 
efficacy of tumour bed irradiation alone. Par-
tial breast irradiation (PBI) using HDR-BT is 
an attractive treatment approach in a group of 
patients with low risk of local recurrence (T1, 
T2, N0, > 40 years old).
ConCluSionS, ControverSieS,  
and future ProSPeCtS
1. The results of numerous retrospective 
and some prospective studies suggest that 
boost dose increases LC (local control) for a 
patient treated with BCT. 2. Young age, posi-
tive or close surgical margins, and EIC should 
be regarded as absolute indications for boost 
irradiation. 3. Interstitial BT boost can be ap-
plied in BCT with low incidence of late side 
effects and with at least similar LTC as per-
cutaneous boost techniques. Furthermore, BT 
is preferable in certain anatomical situations, 
especially in cases of a deep-seated tumour 
bed in large volume breasts. 4. Two sets (pre-
implant and post-implant) of CT scans are re-
quired to improve the implant quality. 5. The 
use of appropriately placed surgical clips to 
demarcate the tumour bed and the use of imag-
ing techniques such as computed tomography 
and ultrasound may substantially increase the 
accuracy in determining the boost volume. In 
addition, it intensifies the probability of local 
tumour control as well as reducing undesir-
able cosmetic results. 6. The external electron 
beam boost usually includes the skin and the 
subcutaneous vessels; nevertheless, the inter-
stitial implant represents the more conformal 
technique, which offers lower rates of late side 
effects, particularly in skin telangiectasia and 
skin fibrosis. 7. Preliminary results with re-
cently developed boost techniques based on 
CT-image 3D conformal BT (IORT, CT-image 
based 3D conformal BT, and 3D virtual BT) 
are encouraging. However, longer follow-up 
and more scientific experience in this matter 
are required to state whether these methods 
might improve local tumour control for breast 
cancer patients treated with BCT.
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